UBS Group Begins Coverage on Ascendis Pharma A/S (NASDAQ:ASND)

Investment analysts at UBS Group started coverage on shares of Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) in a research note issued to investors on Tuesday, MarketBeat reports. The brokerage set a "buy" rating and a $196.00 price target on the biotechnology company's stock. UBS Group's price target would suggest a potential upside of 42.76% from the stock's current price.

ASND has been the topic of several other reports. Citigroup raised their price objective on shares of Ascendis Pharma A/S from $178.00 to $207.00 and gave the company a "buy" rating in a research report on Tuesday, September 17th. Oppenheimer lowered their price objective on Ascendis Pharma A/S from $190.00 to $180.00 and set an "outperform" rating on the stock in a research report on Friday, November 15th. Evercore ISI increased their target price on Ascendis Pharma A/S from $191.00 to $205.00 and gave the stock an "outperform" rating in a research report on Tuesday, September 17th. Cantor Fitzgerald reissued an "overweight" rating and issued a $170.00 price target on shares of Ascendis Pharma A/S in a report on Friday, November 15th. Finally, StockNews.com upgraded Ascendis Pharma A/S from a "sell" rating to a "hold" rating in a research note on Wednesday, November 20th. Two analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $192.07.

Ascendis Pharma A/S Price Performance

Shares of ASND stock traded down $2.99 during trading hours on Tuesday, reaching $137.29. 392,651 shares of the company traded hands, compared to its average volume of 375,963. The firm has a 50-day moving average price of $132.06 and a 200 day moving average price of $133.58. The company has a market cap of $8.33 billion, a P/E ratio of -16.99 and a beta of 0.65. Ascendis Pharma A/S has a 12-month low of $111.09 and a 12-month high of $161.00.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Wilmington Savings Fund Society FSB bought a new position in Ascendis Pharma A/S during the 3rd quarter valued at about $30,000. Groupama Asset Managment bought a new position in shares of Ascendis Pharma A/S during the third quarter valued at approximately $60,000. GAMMA Investing LLC raised its holdings in shares of Ascendis Pharma A/S by 58.0% in the fourth quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company's stock worth $80,000 after buying an additional 214 shares during the period. Signaturefd LLC lifted its stake in shares of Ascendis Pharma A/S by 13.2% during the 3rd quarter. Signaturefd LLC now owns 686 shares of the biotechnology company's stock worth $102,000 after acquiring an additional 80 shares during the last quarter. Finally, Rhumbline Advisers boosted its holdings in Ascendis Pharma A/S by 10.3% during the 2nd quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company's stock valued at $209,000 after acquiring an additional 143 shares during the period.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.